Publications by authors named "Alain Algazi"

47Publications

Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma.

Ann Surg Oncol 2020 Oct 2;27(11):4122-4130. Epub 2020 Jun 2.

Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-020-08648-7DOI Listing
October 2020

Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers.

Am J Clin Dermatol 2019 Dec;20(6):781-796

Cutaneous Oncology Department, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero Street, San Francisco, CA, 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00452-8DOI Listing
December 2019

Treatment modality impact on quality of life for human papillomavirus-associated oropharynx cancer.

Laryngoscope 2020 02 27;130(2):E48-E56. Epub 2019 Mar 27.

Division of Head and Neck Oncologic and Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lary.27937DOI Listing
February 2020

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600 mutant advanced melanoma.

Pigment Cell Melanoma Res 2019 07 13;32(4):603-606. Epub 2019 Apr 13.

UCSF Hematology and Oncology, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12777DOI Listing
July 2019

Ultraviolet light-related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site.

Head Neck 2019 06 11;41(6):E82-E85. Epub 2019 Jan 11.

Department of Anatomic Pathology, University of California San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.25613DOI Listing
June 2019

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.

Immunity 2018 12 11;49(6):1148-1161.e7. Epub 2018 Dec 11.

Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114, USA; Department of Radiology, Massachusetts General Hospital, 185 Cambridge St, CPZN 5206, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2018.09.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301092PMC
December 2018

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

N Engl J Med 2018 Aug;379(8):722-730

From the University of Texas M.D. Anderson Cancer Center, Houston (H.A.T.); Moffitt Cancer Center and Research Institute, Tampa, FL (P.A.F., N.I.K.); University of California-San Francisco, San Francisco (A. Algazi), the Angeles Clinic and Research Institute, Los Angeles (O.H.), Stanford University Hospital, Palo Alto (R.P.T.), and the Department of Medical Oncology, City of Hope, Duarte (K.M.) - all in California; Dana-Farber Cancer Institute, Boston (F.S.H., D.A.R.); University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (S.J.M.); University of Colorado Comprehensive Cancer Center, Aurora (K.L.); University of Michigan, Ann Arbor (C.D.L.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (M.A.P.), Roswell Park Cancer Institute, Buffalo (M.S.E., I.P.), and New York University, Lake Success (A.C.P.) - all in New York; Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); Winship Cancer Institute of Emory University, Atlanta (R.R.K.); University of Pittsburgh Medical Center, Pittsburgh (A.T.); Bristol-Myers Squibb, Princeton, NJ (J.J., A. Avila, S.D.); and Cleveland Clinic-Taussig Cancer Institute, Cleveland (A.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1805453DOI Listing
August 2018

Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma.

J Otolaryngol Head Neck Surg 2018 Apr 25;47(1):28. Epub 2018 Apr 25.

Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40463-018-0273-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922301PMC
April 2018

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

J Clin Oncol 2017 Dec 24;35(36):4050-4056. Epub 2017 Aug 24.

Chiun Hsu, National Taiwan University Hospital, Graduate Institute of Oncology, National Taiwan University College of Medicine, and National Taiwan University Cancer Center, Taipei, Taiwan, Republic of China; Se-Hoon Lee, Seoul National University Hospital, Seoul, South Korea; Samuel Ejadi, Virginia G. Piper Cancer Center, Scottsdale, AZ; Roger B. Cohen, University of Pennsylvania, Philadelphia, PA; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Alain Algazi, University of California, San Francisco, San Francisco, CA; Sanatan Saraf, Pradeep Thanigaimani, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ; Caroline Even, Gustave Roussy, Villejuif; Christophe Le Tourneau, Institut Curie, Paris; Christophe Le Tourneau, INSERM U900 Research Unit, Saint-Cloud, France; Emilie M.J. van Brummelen, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Aaron R. Hansen, Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.3675DOI Listing
December 2017

Are PD-1 antibodies safe for use in metastatic uveal melanoma?

Melanoma Manag 2017 May 10;4(2):79-82. Epub 2017 May 10.

Melanoma Center, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2017-0007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094660PMC
May 2017

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.

Br J Cancer 2017 Apr 21;116(9):1141-1147. Epub 2017 Mar 21.

Division of Hematology-Oncology, Department of Medicine, University of California, San Francisco, Mount Zion A-743, 1600 Divisadero Street, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.70DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418446PMC
April 2017

Head and neck cancer in 2016: A watershed year for improvements in treatment?

Nat Rev Clin Oncol 2017 Feb 6;14(2):76-78. Epub 2016 Dec 6.

Department of Otolaryngology-Head and Neck Surgery, Clinical and Translational Sciences Institute, University of California, San Francisco, 550 16th Street, Box 0558, San Francisco, California 94113, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2016.196DOI Listing
February 2017

Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.

J Natl Cancer Inst 2017 01 26;109(1). Epub 2016 Sep 26.

Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw190DOI Listing
January 2017

Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade.

J Immunother Cancer 2016 20;4:58. Epub 2016 Sep 20.

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero Street, Box 1770, San Francisco, CA 94115 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0162-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028983PMC
September 2016

NCCN Guidelines Insights: Melanoma, Version 3.2016.

J Natl Compr Canc Netw 2016 08;14(8):945-58

From Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Michigan Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; UC San Diego Moores Cancer Center; Fred & Pamela Buffett Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The University of Tennessee Health Science Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; University of Colorado Cancer Center; Aim at Melanoma; Vanderbilt-Ingram Cancer Center; Mayo Clinic Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Yale Cancer Center/Smilow Cancer Hospital; Fox Chase Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; The University of Texas MD Anderson Cancer Center; Duke Cancer Institute; Roswell Park Cancer Institute; Stanford Cancer Institute; Massachusetts General Hospital Cancer Center; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0101DOI Listing
August 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.

JAMA Dermatol 2015 Nov;151(11):1206-1212

Mt Zion Cancer Research Center, Department of Dermatology, University of California-San Francisco (Sanlorenzo, Vujic, Daud, Algazi, Gubens, Luna, Lin, Ortiz-Urda); Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy (Sanlorenzo, Quaglino); Department of Dermatology, The Rudolfstiftung Hospital, Academic Teaching Hospital, Medical University Vienna, Vienna, Austria (Vujic, Rappersberger).

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061067PMC
http://dx.doi.org/10.1001/jamadermatol.2015.1916DOI Listing
November 2015

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Cancer Cell 2015 Feb 15;27(2):240-56. Epub 2015 Jan 15.

Division of Dermatology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2014.11.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326539PMC
February 2015

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

J Clin Oncol 2014 Nov 6;32(33):3697-704. Epub 2014 Oct 6.

Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226803PMC
November 2014

Melanoma immunotherapy.

Cancer Biol Ther 2014 Jun 20;15(6):665-74. Epub 2014 Mar 20.

University of California San Francisco; San Francisco, CA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.28555DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049781PMC
June 2014

Treatment of cutaneous melanoma: current approaches and future prospects.

Cancer Manag Res 2010 Aug 17;2:197-211. Epub 2010 Aug 17.

Department of Medicine, Division of Hematology and Oncology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMR.S6073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004577PMC
August 2010

Biology and treatment of primary central nervous system lymphoma.

Neurotherapeutics 2009 Jul;6(3):587-97

Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nurt.2009.04.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942275PMC
July 2009